Helping Make our Communities Safer. Jaime is a Trial Attorney and Safety Advocate at Atlee Hall, LLP in Lancaster, PA representing seriously injured victims, wrongful death and those harmed by unsafe products and corporate neglect. Contact Jaime at 800-924-2309 or email firstname.lastname@example.org.
Tuesday, October 11, 2016
Study shows J&J’s
Xarelto may cause more serious bleeding than Pradaxa.
Fierce Pharma (10/7, Helfand, 3K) reported on
a study published in JAMA showing that Johnson & Johnson and Bayer’s
Xarelto (rivaroxaban) may cause more serious bleeding than Boehringer
Ingelheim’s Pradaxa (dabigatran). According to the study, Xarelto “was
associated with significant increases in intracerebral hemorrhage and major
extracranial bleeding.” The researchers also found that Xarelto was used up to
three times more often than Pradaxa among American afib patients because
“prescriber misperceptions about bleeding risks with dabigatran, arising from
U.S. Food and Drug Administration receipt of a large number of postmarketing
case reports following its approval.”